OncBioMune Pharmaceuticals, Inc Contracts & Agreements

Secured Convertible Promissory Note dated August 16, 2023 (Filed With SEC on August 21, 2023)

Amended and Restated Security Agreement (Filed With SEC on August 21, 2023)

Agreement and Plan of Merger, dated as of May 23, 2023, by and among IMAC Holdings, Inc., IMAC Merger Sub, LLC and Theralink Technologies, Inc (Filed With SEC on May 26, 2023)

Offer Letter between the Company and Faith Zaslavsky, dated December 5, 2022 (Filed With SEC on December 9, 2022)

Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Filed With SEC on December 1, 2022)

Form of Common Stock Purchase Warrant (Filed With SEC on December 1, 2022)

Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Exchanged Debentures) (Filed With SEC on December 1, 2022)

Placement Agency Agreement by and between the Company and Joseph Gunnar & Co (Filed With SEC on December 1, 2022)

Form of Securities Purchase Agreement (Filed With SEC on December 1, 2022)

Form of Security Agreement (Filed With SEC on December 1, 2022)

Form of Demand Note (Filed With SEC on September 16, 2022)

Form of Convertible Promissory Note for April 2022 (Filed With SEC on May 23, 2022)

Form of Common Stock Purchase Warrant for April 2022 (Filed With SEC on May 23, 2022)

Form of Securities Purchase Agreement for April 2022 (Filed With SEC on May 23, 2022)

Form of Common Stock Purchase Warrant 2 (Filed With SEC on February 3, 2022)

Form of Securities Purchase Agreement (Filed With SEC on February 3, 2022)

Engagement Letter, by and between Carter, Terry & Company and Theralink Technologies, Inc., dated December 15, 2021, as amended (Filed With SEC on February 3, 2022)

Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk effective January 1, 2021 (Filed With SEC on January 13, 2022)

Form of Convertible Promissory Note, dated November 1, 2021 (Filed With SEC on November 5, 2021)

Form of Common Stock Purchase Warrant, issued November 1, 2021 (Filed With SEC on November 5, 2021)

Securities Purchase Agreement, dated November 1, 2021 (Filed With SEC on November 5, 2021)

Employment Agreement, dated June 5, 2020 by and between Dr. Michael Ruxin and OncBioMune Pharmaceuticals, Inc (Filed With SEC on September 27, 2021)

Employment Agreement, dated June 5, 2020 by and between Jeffrey Busch and OncBioMune Pharmaceuticals, Inc (Filed With SEC on September 27, 2021)

Common Stock Purchase Warrant, issued July 30, 2021 (Filed With SEC on August 6, 2021)

Securities Purchase Agreement, dated July 30, 2021 (Filed With SEC on August 6, 2021)

Convertible Secured Promissory Note, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Common Stock Purchase Warrant, issued May 12, 2021 (Filed With SEC on May 19, 2021)

Securities Purchase Agreement, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Security Agreement, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Form of Subscription Agreement (Filed With SEC on April 20, 2021)

Form of Registration Rights Agreement (Filed With SEC on April 20, 2021)

Securities Purchase Agreement, dated September 16, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investor (Filed With SEC on September 22, 2020)

Form of Warrant (Filed With SEC on June 11, 2020)

Exchange Warrant, dated June 5, 2020 (Filed With SEC on June 11, 2020)

Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein (Filed With SEC on June 11, 2020)

Exchange Agreement, dated June 5, 2020, by and between OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, Ph.D (Filed With SEC on June 11, 2020)

Securities Purchase Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. Cavalry Fund I LP and Lincoln Park Capital Fund, LLC (Filed With SEC on June 11, 2020)

Separation Agreement and General Release of Claims between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020 (Filed With SEC on June 11, 2020)

Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020 (Filed With SEC on June 11, 2020)

Asset Purchase Agreement, dated May 12, 2020, between OncBioMune Pharmaceuticals, Inc. and Avant Diagnostics, Inc (Filed With SEC on May 13, 2020)

Description of Capital Stock (Filed With SEC on March 25, 2020)

Note dated September 25, 2019 (Filed With SEC on November 19, 2019)

Warrant dated September 25, 2019 (Filed With SEC on November 19, 2019)

Securities Purchase Agreement dated September 25, 2019 (Filed With SEC on November 19, 2019)

Form of Note (Filed With SEC on August 6, 2019)

Form of Warrant (Filed With SEC on August 6, 2019)

Securities Purchase Agreement (Filed With SEC on August 6, 2019)

Form of Note (Filed With SEC on July 18, 2019)

Form of Warrant (Filed With SEC on July 18, 2019)

Form of Securities Purchase Agreement (Filed With SEC on July 18, 2019)

Form of Note (Filed With SEC on May 2, 2019)

Form of Warrant (Filed With SEC on May 2, 2019)

Form of Securities Purchase Agreement (Filed With SEC on May 2, 2019)

Employment Agreement effective as of December 26, 2018 between OncBioMune Pharmaceuticals, Inc. and Brian Barnett, MD (Filed With SEC on April 1, 2019)

Senior Convertible Note issued March 25, 2019 to Cavalry Fund I LP (Filed With SEC on April 1, 2019)

Securities Purchase Agreement between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP, dated March 25, 2019 (Filed With SEC on April 1, 2019)

Common Stock Purchase Warrant issued March 25, 2019 to Cavalry Fund I LP (Filed With SEC on April 1, 2019)

Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March... (Filed With SEC on February 21, 2019)

Irrevocable Trust Agreement Number F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. as beneficiaries and Banco... (Filed With SEC on February 21, 2019)

Shareholders Agreement among OncBioMune Pharmaceuticals, Inc., Jonathan F. Head, Ph.D., Andrew A. Kucharchuk, Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March... (Filed With SEC on February 21, 2019)

Convertible Redeemable Note, dated as of January 18, 2019 (Filed With SEC on February 4, 2019)

Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and Cerberus Finance Group Ltd (Filed With SEC on February 4, 2019)

Convertible Redeemable Note, dated as of January 18, 2019 (Filed With SEC on January 29, 2019)

Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and LG Capital Funding LLC (Filed With SEC on January 29, 2019)

Securities Purchase Agreement, dated September 24, 2018 (Filed With SEC on November 14, 2018)

Subsidiary Guaranty Agreement, dated September 24, 2018 (Filed With SEC on November 14, 2018)

Pledge Agreement, dated September 24, 2018 (Filed With SEC on November 14, 2018)

Escrow Agreement, dated September 24, 2018 (Filed With SEC on November 14, 2018)

Security Agreement, dated September 24, 2018 (Filed With SEC on November 14, 2018)

Form of Note issued September 24, 2018 (Filed With SEC on November 14, 2018)

Form of Warrants issued September 24, 2018 (Filed With SEC on November 14, 2018)

Securities Purchase Agreement between Cavalry I LP and OncBioMune, Inc., dated November 13, 2018 (Filed With SEC on November 14, 2018)

Note Agreement between Cavalry I LP and OncBioMune, Inc, dated November 13, 2018 (Filed With SEC on November 14, 2018)

Warrants Agreement between Cavalry I LP and OncBioMune, Inc, dated November 13, 2018 (Filed With SEC on November 14, 2018)

Form of Note (Filed With SEC on July 31, 2018)

Form of Securities Purchase Agreement (Filed With SEC on July 31, 2018)

Form of Securities Purchase Agreement dated January 29, 2018 (Filed With SEC on May 31, 2018)

Form of Note issued January 29, 2018 (Filed With SEC on May 31, 2018)

Form of Warrant issued January 29, 2018 (Filed With SEC on May 31, 2018)

Security Agreement dated January 29, 2018 (Filed With SEC on May 31, 2018)

Pledge Agreement dated January 29, 2018 (Filed With SEC on May 31, 2018)

Subsidiary Guarantee dated January 29, 2018 (Filed With SEC on May 31, 2018)

Form of Securities Purchase Agreement dated March 13, 2018 (Filed With SEC on May 31, 2018)

Form of Note issued March 13, 2018 (Filed With SEC on May 31, 2018)

Form of Warrant issued March 13, 2018 (Filed With SEC on May 31, 2018)

Security Agreement dated March 13, 2018 (Filed With SEC on May 31, 2018)

Pledge Agreement dated March 13, 2018 (Filed With SEC on May 31, 2018)

Subsidiary Guarantee dated March 13, 2018 (Filed With SEC on May 31, 2018)

ForbearanceAgreement (Filed With SEC on June 6, 2017)

NON-QUALIFIEDSTOCK OPTION AGREEMENT FOR DIRECTORS (Filed With SEC on April 21, 2017)

PARTIES (Filed With SEC on March 13, 2017)

Representations (Filed With SEC on March 13, 2017)

STOCKHOLDERS’AGREEMENT datedas of March10, 2017 among ONCBIOMUNEPHARMACEUTICALS, INC. and THESTOCKHOLDERS PARTY HERETO (Filed With SEC on March 13, 2017)

FORMOF (Filed With SEC on March 13, 2017)

FORMOF AMENDMENTTO EMPLOYMENT AGREEMENT AndrewKucharchuk (Filed With SEC on March 13, 2017)

FORMOF NON-QUALIFIEDSTOCK OPTION AGREEMENT (Filed With SEC on March 13, 2017)

AMENDEDAND RESTATED SECURITIESPURCHASE AGREEMENT (Filed With SEC on November 28, 2016)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on November 21, 2016)

FORMOF 10%original issue discount 10%Senior Convertible NOTE DUEJuly 18, 2017 (Filed With SEC on November 21, 2016)

COMMONSTOCK PURCHASE WARRANT OncBioMunePharmaceuticals, Inc. (Filed With SEC on November 21, 2016)

FORMOF SECURITY AGREEMENT (Filed With SEC on November 21, 2016)

FORMOF PLEDGE AGREEMENT (Filed With SEC on November 21, 2016)

FORMOF SUBSIDIARY GUARANTY (Filed With SEC on November 21, 2016)

SHAREHOLDERSaGREEMENT byand between OncbiomuneMéxico, s.A. de c.v. asthe Company, and VitelLaboratorios, S.A. de C.V. and OncBioMune Pharmaceuticals Inc. as Shareholders Datedas... (Filed With SEC on August 26, 2016)

SABRCapital Management LLC 335 Madison Avenue, Suite 1100, New York, New York 10017 (Filed With SEC on May 16, 2016)

Account (Filed With SEC on May 16, 2016)

EMPLOYMENTAGREEMENT (Filed With SEC on February 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on February 5, 2016)

PURCHASEAGREEMENT (Filed With SEC on November 20, 2015)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on November 20, 2015)

PURCHASEAGREEMENT (Filed With SEC on October 26, 2015)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on October 26, 2015)

AMENDMENT#1 TO THE SHARE EXCHANGE AGREEMENT DATEDJUNE 22, 2015 (Filed With SEC on September 8, 2015)

SHAREEXCHANGE AGREEMENT Dated June22, 2015 byand among QUINTMEDIA, INC., a Nevada Corporation asthe Acquiror and Parent. and ONCBIOMUNE,INC., aLouisiana corporation and... (Filed With SEC on June 24, 2015)

DEBTSETTLEMENT AGREEMENT (Filed With SEC on June 24, 2015)

DEBTSETTLEMENT AGREEMENT (Filed With SEC on March 16, 2015)

Form of subscription agreement with promissory note attached (Filed With SEC on October 14, 2014)

Form of subscription agreement with promissory note attached (Filed With SEC on July 21, 2014)

Form of subscription agreement with promissory note attached (Filed With SEC on April 4, 2014)

Form of subscription agreement with promissory note attached (Filed With SEC on February 18, 2014)

Form of Private Placement Subscription Agreement (Filed With SEC on December 2, 2013)

Form of Warrant Certificate (Filed With SEC on December 2, 2013)

Form of Private Placement Subscription Agreement including Form of Promissory Note (Filed With SEC on September 26, 2013)

Form of Promissory Note Amendment dated August 31, 2013 (Filed With SEC on September 26, 2013)

Business Development/Advisory Services Agreement dated March 82013 with Phys Pharma LLC (Filed With SEC on June 28, 2013)

Web Site Asset Purchase Agreement dated May 17, 2013 between Lakefield Media Holding AG, Flawsome XLerator GmBH and Pediatrix Inc (Filed With SEC on June 28, 2013)

Consulting Agreement dated May 29, 2013 with Flawsome XLerator GmBH (Filed With SEC on June 28, 2013)

Form of $50,000 Promissory Note Amendment dated July 25, 2012 (Filed With SEC on July 31, 2012)

Form of $250,0000 Promissory Note Amendment dated July 25, 2012 (Filed With SEC on July 31, 2012)

Form of Promissory Note Amendment dated July 25, 2012 (Filed With SEC on July 27, 2012)

Termination Agreement between Apricus Biosciences, Inc and PediatRx Inc. dated June 27, 2012 (Filed With SEC on June 28, 2012)

Asset Purchase Agreement dated February 21, 2012 with Apricus Biosciences, Inc (Filed With SEC on May 18, 2012)

Co-Promotion Agreement dated February 21, 2012 with Apricus Biosciences, Inc. (portions of the exhibit have been omitted pursuant to a request for confidential treatment) (Filed With SEC on May 18, 2012)

Form of $50,000 Promissory Note Amendment dated April 19, 2012 (Filed With SEC on May 18, 2012)

Form of $250,000 Promissory Note Amendment dated April 19, 2012 (Filed With SEC on May 18, 2012)

Binding term sheet for (1) Granisol and Aquoral US Co-promotion Agreement, (2) Sale of ex-US rights for Granisol and non-binding term sheet for merger of PediatRx Inc. and Apricus... (Filed With SEC on January 27, 2012)

Amendment to Stock Option Agreement, Waiver and Release dated December 15, 2011 with Jorge Rodriguez (Filed With SEC on January 17, 2012)

Form of independent contractor agreement (Filed With SEC on September 30, 2011)

Form of stock option agreement (Filed With SEC on September 15, 2011)

Co-promotion agreement with Bi-Coastal Pharmaceuticals effective September 12, 2011 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) (Filed With SEC on September 14, 2011)

Form of stock option agreement (Filed With SEC on July 26, 2011)

Form of Promissory Note Amendment dated May 23, 2011 (Filed With SEC on May 23, 2011)

Form of Promissory Note Amendment dated May 18, 2011 (Filed With SEC on May 18, 2011)

Form of Private Placement Subscription Agreement including Form of Promissory Note dated May 6, 2011 (Filed With SEC on May 11, 2011)

Form of stock option agreement (Filed With SEC on March 7, 2011)

2011 Stock Option Plan (Filed With SEC on February 22, 2011)

Lock-up Agreement dated February 9, 2011 with Cameron Durrant (Filed With SEC on February 10, 2011)

Lock-up Agreement dated February 9, 2011 with David Tousley (Filed With SEC on February 10, 2011)

Cancellation Agreement dated February 9, 2011 with Cameron Durrant (Filed With SEC on February 10, 2011)

Cancellation Agreement dated February 9, 2011 with David Tousley (Filed With SEC on February 10, 2011)

Form of Private Placement Subscription Agreement (Filed With SEC on December 2, 2010)

Form of Shares for Debt Subscription Agreement (Filed With SEC on December 2, 2010)

Management Stock Agreement made effective July 1, 2010 with Cameron Durrant (Filed With SEC on November 3, 2010)

Management Stock Agreement made effective July 1, 2010 with David Tousley (Filed With SEC on November 3, 2010)

Form of Private Placement Subscription Agreement (Filed With SEC on November 3, 2010)

Consulting Agreement effective July 1, 2010 with Cameron Durrant (Filed With SEC on September 28, 2010)

Form of Private Placement Subscription Agreement (Filed With SEC on September 28, 2010)

Form of promissory note dated September 16, 2010 (Filed With SEC on September 28, 2010)

Termination Agreement effective July 1, 2010 with Cameron Durrant (Filed With SEC on September 28, 2010)

Employment Agreement effective July 1, 2010 with David L. Tousley (Filed With SEC on September 16, 2010)

Employment Agreement effective July 1, 2010 with Jorge Rodriguez (Filed With SEC on September 16, 2010)

Form of Private Placement Subscription Agreement (Filed With SEC on July 29, 2010)

Form of promissory note dated July 26, 2010 (Filed With SEC on July 29, 2010)

Asset Purchase Agreement dated July 22, 2010 with Cypress Pharmaceuticals, Inc. (portions of the exhibit have been omitted pursuant to a request for confidential treatment) (Filed With SEC on July 28, 2010)

Assignment and Assumption of Contract dated July 22, 2010 with Cypress Pharmaceuticals, Inc (Filed With SEC on July 28, 2010)

Consent to Assignment by Therapex and E-Z-EM Canada Inc (Filed With SEC on July 28, 2010)

Manufacturing and Supply Agreement dated July 22 2010 between Cypress Pharmaceuticals, Inc. and Therapex, a division of E-Z-EM Canada Inc. (portions of the exhibit have been... (Filed With SEC on July 28, 2010)

Form of Private Placement Subscription Agreement (Filed With SEC on July 9, 2010)

Consulting Agreement with Cameron Durrant dated May 28, 2010 (Filed With SEC on June 28, 2010)

Letter of Intent with Granisol Oral Solution (Filed With SEC on June 28, 2010)

Form of Private Placement Subscription Agreement (Filed With SEC on June 18, 2010)

Form of Private Placement Subscription Agreement dated June 15, 2009 (Filed With SEC on June 16, 2009)

Form of promissory note dated June 15, 2009 (Filed With SEC on June 16, 2009)

Form of Private Placement Subscription Agreement (Filed With SEC on November 6, 2008)

Category

Industry

Companies

Contracts

OncBioMune Pharmaceuticals, Inc Contracts & Agreements